Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban for Isolated Distal Deep Vein Thrombosis
NCT04981327Phase 3Not yet recruiting
- Start
- Sep 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, single-blind trial of apixaban in isolated distal deep vein thrombosis (IDDVT). Primary endpoint: Rate of symptomatic VTE, major bleeding and clinically relevant non major bleeding (CRNMB), VTE and bleeding related death at 1 year. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
apixaban
03
Conditions
isolated distal deep vein thrombosis (IDDVT)
Beyond the preview
Go deeper on NCT04981327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04981327.